PT  - JOURNAL ARTICLE
AU  - O’Donoghue, Ashley L.
AU  - Reichheld, Alyse
AU  - Anderson, Timothy S.
AU  - Zera, Chloe A.
AU  - Dechen, Tenzin
AU  - Stevens, Jennifer P.
TI  - Decline in prenatal buprenorphine/naloxone fills during the COVID-19 pandemic in the United States
AID  - 10.1101/2021.10.08.21264760
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.08.21264760
4099  - http://medrxiv.org/content/early/2021/10/11/2021.10.08.21264760.short
4100  - http://medrxiv.org/content/early/2021/10/11/2021.10.08.21264760.full
AB  - Background and Aims Pregnancy provides a critical opportunity to engage women with substance use disorder in care. Buprenorphine/naloxone treatment is associated with improved pregnancy and fetal outcomes, but prior to the COVID-19 pandemic, there were multiple barriers to accessing buprenorphine/naloxone during pregnancy. Care disruptions during the pandemic may have further exacerbated these already existing barriers. To quantify these changes, we examined trends in the number of individuals filling prescriptions for prenatal buprenorphine/naloxone prescriptions during the COVID-19 pandemic.Methods We estimated an interrupted time series model using linked national pharmacy claims and medical claims data from May 2019 to December 2020. We estimated changes in the level and trend in the monthly number of individuals filling prescriptions for prenatal buprenorphine/naloxone during the COVID-19 pandemic. We then stratified our analyses by payer.Results We identified 2,947 pregnant patients filling buprenorphine/naloxone prescriptions. Before the pandemic, there was positive growth in the monthly number of individuals filling prescriptions for prenatal buprenorphine/naloxone (4.83% (95% confidence interval (CI): 3.40% to 6.26%). During the pandemic, the monthly growth rate in individuals filling prescriptions for prenatal buprenorphine/naloxone declined for both patients on commercial insurance and patients on Medicaid (all payers: -5.53% (95% CI: -7.28% to -3.78%); Medicaid: -7.66% (95% CI: -10.42% to -4.90%); Commercial: -3.59% (95% CI: -5.53% to -1.66%)).Conclusion The number of pregnant individuals filling buprenorphine/naloxone prescriptions was increasing prior to the pandemic, but this growth has been lost during the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementO'Donoghue, Dechen, and Stevens are funded by an unrestricted philanthropic gift from Google.org. Google.org had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval, of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research used only deidentified data and was classified as exempt from written informed consent by the Beth Israel Deaconess Medical Center institutional review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data, technology, and services used in the generation of these research findings are restricted access and were generously supplied pro bono by the COVID-19 Research Database partners. Applications for access can be found at the following URL: https://covid19researchdatabase.org/. https://covid19researchdatabase.org/